impact factor, citescore
logo
 

shopping cart

Confirmation
purchase
Item
Code
Item DescriptionPrice
CER17644A Phase 3, 56-week, randomised, double-blind, placebo-controlled study (OA-11) utilising patient-reported and radiographic outcomes evaluating the efficacy and safety of a lorecivivint injection in patients with moderate to severe knee osteoarthritis20.00 €
 Subtotal 20.00 €